Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Chief Financial Officer | March 14, 2023 | March 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-03-14 | Direct | 275,000 |
Reported balance
After 2023-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-14 · Grant · Acquired 275,000 · Balance 275,000 F1: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2023 Filed Mar 16, 2023 20:27 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-23-006908 · rdgdoc.xml · derivative · entry 1 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-03-14 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 20:45 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 274,875 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-050081 · doc4.xml · derivative · entry 1 Beyer Russell P · CIK 0001889754 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,875 Underlying: Common Stock · 274,875 shares Expires 2032-09-13 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| March 16, 2022 Filed Mar 19, 2022 01:15 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-22-011666 · doc4.xml · derivative · entry 1 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-03-16 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:45 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001493152-21-029395 · ownership.xml · derivative · entry 1 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-11-17 F1 · shares: Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. Read SEC document |
| October 26, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | SaleCommon Stock | 278 | $7.90 | $2,196.20 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 4 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · kind: The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| October 25, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 129 | $7.78 | $1,003.62 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 3 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 278 Read SEC document |
| October 18, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 2,475 | $10.10 | $24,997.50 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 1 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,475 F1 · date: This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. Read SEC document |
| September 29, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 10 | $10.08 | $100.80 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 6 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 15 F1 · date: This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. Read SEC document |
| September 28, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 5 | $10.07 | $50.35 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 5 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 5 F1 · date: This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. Read SEC document |
| September 28, 2021 Filed Nov 16, 2021 20:09 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantCommon Stock | 149 | $10.08 | $1,501.92 |
DisclosureSEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 2 Beyer Russell P · CIK 0001889754 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 149 F1 · date: This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.